A MORE PROMISING FUTURE FOR PATIENTS

We have discovered treatments that have the therapeutic potential to transform the lives of patients with neurological disorders.

SCIENCE-BASED INNOVATION WITH BREAKTHROUGH OUTCOMES

Based on fundamental discoveries in the mechanisms of synaptic plasticity and neuronal cell death, we have identified potential treatments for Neurodegenerative Disorders that have eluded researchers for decades.

About NeurAegis

NeurAegis is a preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including concussion and epilepsy. Founded in 2016, our initial focus is developing first-in-class, novel protease inhibitors for mild traumatic brain injury (concussion) where there are currently no FDA approved treatments.

For more information, follow us on LinkedIn.

Press Release

NeurAegis Scientific Founder Michel Baudry Awarded $3.8M Grant from the Department of Defense to Advance Product Candidate for Treating Traumatic Brain Injury and Concussion

Proven Leadership

NeurAegis is led by a team with deep, relevant experience for developing novel therapeutics.

Michel Baudry, PhD

Michel Baudry, PhD

Chief Scientific Officer

Joe Blanchard, MBA

Joe Blanchard, MBA

President and Chief Executive Officer

Mike Palfreyman, PhD

Mike Palfreyman, PhD

Drug Development Advisor